Alharbi, Adel
Yousef, Abdullah
Zubani, Amal
Alzahrani, Mohammad
Al-Hindi, Mohammad
Alharbi, Saleh
Alahmadi, Turki
Alabdulkarim, Hana
Kazmierska, Paulina
Beuvelet, Matthieu http://orcid.org/0000-0001-5450-3613
Funding for this research was provided by:
Sanofi
AstraZeneca
Article History
Received: 12 December 2023
Accepted: 19 January 2024
First Online: 15 February 2024
Declarations
:
: Matthieu Beuvelet is an employee of Sanofi and may hold shares/stocks in Sanofi. Paulina Kazmierska is employed by Evidera, a part of Thermo Fisher Scientific, which received funding for research from Sanofi and AstraZeneca. Adel Alharbi, Abdullah Yousef, Amal Zubani, Mohammad Alzahrani, Mohammad Alhindi, Saleh Alharbi, Turki Alahmadi and Hana Alabdulkarim have no relevant financial or non-financial interests to disclose. Nirsevimab is being developed and commercialized in partnership between AstraZeneca and Sanofi.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.